Administration of yunnan baiyao or xingnaojing in patients with moderate-to-sever traumatic brain injury and craniotomy
AssigneeLotus Biotech.com LLC
InventorGuoqiang Xing
Life of this patent
Estimating the term…
Abstract
A method of treating a patient with moderate-to-severee traumatic brain injury (TBI) undergoing emergency craniotomy includes administering, in addition to orthodox therapy (OT), intravenous Xingnaojing (XNJ) for seven consecutive days in an intensive care setting, wherein acute postoperative neurological recovery is improved as measured by Glasgow Coma Scale (GCS) during postoperative Days 1, 3, 5, and 7, wherein long-term functional outcome is improved as measured by Glasgow Outcome Scale (GOS) and Karnofsky Performance Status (KPS) at 30 and 90 days, and wherein secondary-injury biomarkers are modulated by reducing serum S100B and preserving or restoring serum superoxide dismutase (SOD) activity relative to OT alone.
Claims16
A method of treating a patient with moderate-to-severee traumatic brain injury (TBI) undergoing emergency craniotomy, the method comprising administering, in addition to orthodox therapy (OT), intravenous Xingnaojing (XNJ) for seven consecutive days in an intensive care setting, wherein acute postoperative neurological recovery is improved as measured by Glasgow Coma Scale (GCS) during postoperative Days 1, 3, 5, and 7, wherein long-term functional outcome is improved as measured by Glasgow Outcome Scale (GOS) and Karnofsky Performance Status (KPS) at 30 and 90 days, and wherein secondary-injury biomarkers are modulated by reducing serum S100B and preserving or restoring serum superoxide dismutase (SOD) activity relative to OT alone.
A method of improving neurological recovery after emergency craniotomy in a moderate-to-severee TBI patient, comprising administering XNJ in an amount effective to improve Glasgow Coma Scale (GCS) score during a 7-day postoperative recovery period.
A method of modulating secondary-injury biomarkers after emergency craniotomy in a moderate-to-severee TBI patient, comprising administering XNJ in an amount effective to (i) reduce serum S100B and/or (ii) preserve or increase serum superoxide dismutase (SOD) activity relative to control.
Dependencies are inferred from the claim text.